Symbiotec Pharmalab Limited IPO
ListedMainboardPharmaceuticals
71.20×
Subscribed
Price band
₹988 – ₹988
Lot size
15
1 lot = ₹14,820
Issue size
₹1.76k Cr
Open – close
24 Aug 2026
to 27 Aug 2026
Listing
01 Sept 2026
What the filing actually says
Our read of the offer document and the exchange data — not the issuer's summary of itself
Weak4 of 7 dimensions read
The disclosed numbers are weak — 3 of 6 signals read negative
Strength37/100
- Conservative balance sheetDebt/equity of 0.34×
- Almost entirely an exit91.5% of the issue is an offer for sale — nearly all of the money goes to existing shareholders, not into the company
- Proceeds mostly repay debt₹113 Cr of the ₹150 Cr raised repays borrowings — deleveraging rather than expansion
- Qualified audit opinionQualifications/modifications under section Other Legal and Regulatory Requirements on matters included in the Companies (Auditor’s Report) Order, 2020 and modifications relating to
- 2 high-severity disclosures91% of the offer is an Offer for Sale, so most proceeds go to selling shareholders, not the company.
- Institutions bid heavilyQIB portion subscribed 172.03×
Every line above is arithmetic on a figure shown elsewhere on this page - no model, no opinion. It describes the quality of the offering as disclosed, and is pulled toward neutral to reflect how much the document leaves unsaid. It is not a prediction of the listing price, and it is not advice to apply.
Dates
The issuer's tentative timetable — a date passing is not confirmation the step completed
- Opens24 Aug 2026
- Closes27 Aug 2026
- Allotment28 Aug 2026
- Listing01 Sept 2026
Demand and your odds
How the book filled, and what that means for an application
Subscription by category
Qualified institutionalQIB172.03x
Non-institutionalNII / HNI73.61x
Retail individualRII12.86x
Chance of allotment
Retail12.86× subscribed
~1 in 12.9
Minimum 1 lot · 15 shares · ₹14,820 blocked
Retail is 12.86× subscribed. Allotment is a lottery on a single lot, so roughly 1 in 12.9 applications gets one lot. Bidding for extra lots does not improve these odds.
HNI / NII73.61× subscribed
~1 in 73.6
Minimum 14 lots · 210 shares · ₹2,07,480 blocked
HNI is 73.61× subscribed. This category is allotted proportionately, so a bid receives roughly 1/73.6 of the shares applied for, subject to the minimum-lot draw.
Derived from SEBI's allotment mechanics and the subscription figures beside it. Retail allotment is a lottery on a single lot, so applying for more lots does not improve your chance of getting something.
The offering
Terms, structure and who is selling
Terms
Price band₹988 – ₹988
Face value₹2
Lot size15shares
Minimum application₹14,820at cut-off
Total issue size₹1.76k Cr
Fresh issue₹150 Cr
Offer for sale₹1.61k Cr
Listing atMainboard
Company & valuation
Debt / equity0.34×
ISININE899I01028
RegistrarLINK
91.5% of this issue is an offer for sale. That money goes to existing shareholders selling their stake, not into the company. The business receives only the fresh-issue portion.
What the money is for
Stated use of the net proceeds
- 01Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company₹112.5 Cr
- 02General corporate purposesnot stated
Objects with no stated amount — typically general corporate purposes — are funded from whatever remains, so the quantified figures do not sum to the whole issue.
Risks worth reading
Ranked by our severity assessment, not by the order the prospectus prints them
Mostly an exithigh
91% of the offer is an Offer for Sale, so most proceeds go to selling shareholders, not the company.
Auditor qualificationhigh
Qualifications/modifications under section Other Legal and Regulatory Requirements on matters included in the Companies (Auditor’s Report) Order, 2020 and modifications relating to the maintenance of books of account and other matters connected therewith including modifications related to audit trai
mediumOur revenue is highly concentrated in the sale of APIs, which constituted 96.07%, 99.10% and 100.00% of revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand for APIs, and our top products in particular, or disruption in production, could have an adverse effec
mediumOur top five products contributed 62.27%, 63.16% and 60.37% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand for API products, and our top products in particular, or a temporary or permanent discontinuation in our manufacturing operations for such
mediumOur manufacturing facilities are subject to periodic inspections and audits by regulatory authorities and our customers. Any manufacturing or quality control failures may subject us to regulatory action, damage our reputation and have an adverse effect on our business, results of operations, financi
Litigation
Except as stated below, there are no outstanding (i) criminal proceedings involving the Company, Subsidiaries, Directors or Promoters and Key Managerial Personnel and Senior Management; (ii) actions by regulatory authorities and statutory authorities involving the Relevant Parties and Key Managerial Personnel and Senior Management; (iii) disciplinary actions including penalties imposed by SEBI or stock exchanges against promoters in the last five financial years; (iv) outstanding claims related to direct and indirect taxes involving the Relevant Parties; and (v) other outstanding litigation involving the Relevant Parties (including civil litigation or arbitration proceedings) which have been determined to be material pursuant to the Materiality Policy. The Materiality Threshold is ₹51.12 million. Pre-litigation notices received from third parties (excluding governmental / tax / statutory / regulatory / judicial authorities or notices threatening criminal action) shall in any event not be considered as litigation until impleaded as a party.
Positives the filing discloses (1)
Low leverage
Debt-to-equity of 0.34x.
What happened to comparable issues
The last 8 issues to list with a recorded opening price, most comparable first
Median listing gain
+11.1%
Listed up
6 of 8
Best
+90.0%
Shanti Inorganics
Worst
-0.7%
Mopshop Distribution
Gaja Alternative Asset Management Limitedsame segment
31.2× sub+15.6%
Juniper Green Energy Limitedsame segment
7.9× sub+8.9%
131.8× sub+90.0%
1.6× sub+0.0%
-0.7%
138.6× sub+22.1%
1.5× sub+6.9%
46.2× sub+13.4%
Past issues are context, not a forecast — this issue is a different company at a different price. We show it because "how have issues like this one actually opened" is a question with a real answer, and grey-market premium is not that answer.
About Symbiotec Pharmalab Limited
Symbiotec Pharmalab is a pharmaceutical and biotechnology company involved in the development and manufacturing of active pharmaceutical ingredients (APIs), biotechnology products, and complex injectables. Its operations span three platforms — organic chemistry, biotechnology, and complex injectables. The company has a portfolio of over 60 corticosteroid and steroid hormone APIs, including hydrocortisones, betamethasone, methylprednisolones, progesterones, estrogens, and testosterone. It also provides contract development and manufacturing organisation (CDMO) services to pharmaceutical and nutraceutical companies. As of March 31, 2026, the company had two operational API manufacturing facilities at Rau and Pithampur in Madhya Pradesh. It has also commissioned a biomanufacturing facility at Ujjain and a complex injectables facility at Mhow, Madhya Pradesh. The company operates three R&D centres in Indore focused on organic chemistry, biotechnology and complex injectables. Its products and services have been supplied to over 200 customers across more than 40 countries. Use of proceeds: The IPO consists of both a fresh issue and an offer for sale. Proceeds from the offer for sale segment will be directed to the respective selling shareholders, whereas the net proceeds from the fresh issue will be utilised for the following purposes: Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company — Rs 112.5 crore General corporate purposes
Founded 2002MD Mr. Anil SatwaniSector Pharmaceuticals
Offer documents
The primary sources everything above is drawn from
Common questions
How many times is the Symbiotec Pharmalab Limited IPO subscribed?
Symbiotec Pharmalab Limited is subscribed 71.20× overall (QIB 172.03×, NII 73.61×, retail 12.86×). Subscription keeps changing until the issue closes; the final basis of allotment is published by the registrar, LINK.
What is the minimum investment in the Symbiotec Pharmalab Limited IPO?
One lot is 15 shares, so a retail application at the ₹988 cut-off price blocks ₹14,820. Retail applications are capped at ₹2,00,000; above that you bid in the HNI category, where allotment is proportionate rather than by lottery.
What are the chances of allotment in the Symbiotec Pharmalab Limited IPO?
The retail portion is subscribed 12.86×, so allotment is by lottery and the odds of receiving at least one lot are roughly 1 in 13. Applying for more lots does not improve the chance of getting something — every retail applicant competes for the same single minimum lot.
When is the Symbiotec Pharmalab Limited IPO allotment date?
Allotment is scheduled for 2026-08-28, with listing on 2026-09-01. These dates are the issuer's tentative timetable — a date passing is not confirmation that the step completed. Allotment status is published by the registrar, LINK.
Disclaimer. Figures are compiled from the issuer's offer document and exchange-published bidding data. Subscription changes until the issue closes, and the final basis of allotment is published by the registrar. Grey-market premium is unofficial and is not a forecast. Nothing here is investment advice or a recommendation — read the offer document and consult a SEBI-registered adviser before applying.